Clinical Trial Update: A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Clinical trial update for sacituzumab govitecan (IMMU-132) in endometrial carcinoma, a Phase 2 study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma

Drugs mentioned

• Trodelvy (sacituzumab govitecan) (sacituzumab govitecan)

Snippet

Sponsor: Yale University | Conditions: Endometrial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING